This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Allergan (AGN) Avycaz Label to Include New Phase III Data
by Zacks Equity Research
Allergan plc (AGN) announced that its supplemental new drug application (sNDA) for antibiotic Avycaz has been approved by the FDA. Allergan is looking to include new data from two phase III trials, RECAPTURE and REPRISE, in the drug???s label.
Will Eli Lilly's (LLY) Earnings Surpass Estimates in Q4?
by Zacks Equity Research
We expect Eli Lilly and Company (LLY) to beat expectations when it reports fourth-quarter and full-year 2016 earnings results on Jan 31, before market opens.
Teva's (TEVA) Pain Drug Vantrela ER Receives FDA Approval
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) announced that the FDA has approved Vantrela ER for the treatment of pain which is severe enough to require daily, around-the-clock, long-term opioid treatment.
Lilly to Boost Migraine Pipeline with $960M CoLucid Buyout
by Zacks Equity Research
Eli Lilly and Company (LLY) announced that it plans to buy Cambridge, MA-based biotech firm CoLucid Pharmaceuticals, Inc. (CLCD) for approximately $960 million in cash.
Lilly-Incyte Rheumatoid Arthritis Drug PDUFA Date Extended
by Zacks Equity Research
Eli Lilly and Company (LLY) and Incyte Corporation (INCY) announced that the FDA has extended the time to review the company's NDA for baricitinib for the treatment of rheumatoid arthritis (RA).
Lilly Wins Appeal Against Teva in Alimta Patent Lawsuit
by Zacks Equity Research
Eli Lilly and Company (LLY) announced that it has received a favorable ruling in a lawsuit against generic drugmaker Teva Pharmaceutical Industries Limited (TEVA) related to the infringement of a vitamin regimen patent for its cancer drug Alimta.
New Strong Sell Stocks for January 11th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Wednesday
Merrimack (MACK) Sells Onivyde Rights to Ipsen for $1B
by Zacks Equity Research
Merrimack Pharmaceuticals, Inc. (MACK) announced that it has entered into an agreement with Ipsen for $1.0 billion for Onivyde.
Stock Market News for January 09, 2017
by Zacks Equity Research
Benchmarks posted modest gains on Friday following a solid December U.S. jobs report
Impax (IPXL) Applies for Generic Aubagio; Sanofi Files Lawsuit
by Zacks Equity Research
Impax Laboratories, Inc. (IPXL) announced that it has filed an Abbreviated New Drug application (ANDA) with the FDA for a generic version of Sanofi's Aubagio (teriflunomide) tablets, 14 mg.
Teva Falls on Disappointing 2017 Sales & Earnings Guidance
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) provided a weaker-than-expected sales and earnings guidance for 2017, seeing that its blockbuster multiple sclerosis drug, Copaxone, is reeling under competitive pressures.
Here's Why Teva Pharmaceuticals is Plunging Today
by Madeleine Johnson
On Friday, shares of Teva Pharmaceuticals Industries (TEVA) are plunging, down almost 7.7% in late-afternoon trading after the company announced weaker-than-expected 2017 guidance.
Teva Settles Foreign Bribery Charges with U.S. Government
by Zacks Equity Research
Teva (TEVA) announced that it has completed negotiations with the U.S. government over violations of the Foreign Corrupt Practices Act.
Allergan to Buy LifeCell to Boost Regenerative Medicine Suite
by Zacks Equity Research
Allergan plc (AGN) announced that it has signed a definitive agreement to acquire LifeCell, the regenerative medicine unit of Texas-based privately held company Acelity for $2.9 billion in cash.
Mylan (MYL) Launches Authorized Generic EpiPen at $300
by Zacks Equity Research
Mylan (MYL) announced the launch of the first generic version of its life-saving allergy treatment, EpiPen, at more than 50% discount to the branded product.
20 States Sue Teva, Mylan & Other Drug Companies for Price Fixing
by Arpita Dutt
The lawsuit and the DoJ antitrust probe pose headline risk for generic companies like Mylan (MYL) and Teva (TEVA).
Generic Stocks Feel Pricing Heat, 1st Charges Filed in DoJ Antitrust Probe
by Arpita Dutt
Key generic drugmakers including Teva (TEVA) saw their shares slip on news that the first charges have been filed in the investigation related to generic drug pricing.
Teva Copaxone EU Label to Omit Pregnancy Contraindication
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) announced that it has received a positive outcome to remove the pregnancy contraindication from the label of its key drug Copaxone in the EU.
Stock Market Roundup Dec. 6: CMG, TEVA, Oil Futures Fall
by Madeleine Johnson
Although it was a relatively sound trading day overall, Tuesday was marred by nervousness and hesitation for some struggling companies and oil futures.
Here's Why Teva Pharmaceutical's (TEVA) Stock Is Down Today
by Ryan McQueeney
Shares of Teva Pharmaceutical Industries (TEVA) slipped over 5.8% in morning trading Tuesday after the company announced a change in upper-level management.
Top Research Reports for 21st November, 2016
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Coca-Cola (KO), Disney (DIS) and Danaher (DHR).
Top Research Reports for August 19, 2016
by Sheraz Mian
Today's must-read reports are for Verizon (VZ), Comcast (CMCSA) and Teva (TEVA).
Stock Market News for August 05, 2016
by Zacks Equity Research
Stock Market News for May 10, 2016
by Zacks Equity Research
Benchmarks closed mixed on Monday after gains in healthcare stocks offset declines in energy stocks
Deckers and Teva: This Week's Top Value Stocks
by Tracey Ryniec
Value stock strategist, Tracey Ryniec, profiles Deckers Outdoor Corporation (DECK) and Teva Pharmaceuticals (TEVA).